Blood test could predict who wins against liver cancer

NCT ID NCT05044676

Summary

This study aimed to find a way to predict which patients with advanced liver cancer would benefit from a specific immunotherapy drug combination. Researchers planned to check patients' blood for certain immune cells before and after starting treatment to see if those cells could act as a predictor. The goal was to help doctors know in advance which patients are most likely to respond well to this treatment, so care could be personalized. The study was terminated early after enrolling only four participants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Service hépato-gastroentérologie, Hôpital la Pitié-Salpêtrière

    Paris, France, 75013, France

Conditions

Explore the condition pages connected to this study.